Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIK-ORL phase II trial of BKM120 monotherapy in recurrent or metastatic head and neck cancer
2012-002403-18Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in head and neck cancer (HNC), sponsored by Centre Léon Bérard. Primary endpoint: Disease control rate at 2 months. Started Sep 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2012-002403-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002403-18.